via online.wsj.com
WASHINGTON --A proposal that would ban patent-settlements between brand-name pharmaceutical companies and makers of generic medicines won't be included in legislation overhauling the U.S. health-care system.
The proposal had the support of the Federal Trade Commission and would have made it difficult for brand-name companies to settle patent challenges to their drugs brought by makers of cheaper, generic alternatives. The legislative amendment was dropped Wednesday.
1 comment:
It should be patient's decision whether he will take brand or generic drug.
Post a Comment